ATE194920T1 - Pro-prodrugs, ihre herstellung und anwendung - Google Patents

Pro-prodrugs, ihre herstellung und anwendung

Info

Publication number: ATE194920T1
Authority: AT; Austria
Prior art keywords: prodrugs; pro; production; suited; drugs
Prior art date: 1993-09-22

Application number

AT94114195T

Other languages

English (en)

Inventor

Klaus Bosslet

Joerg Czech

Dieter Hoffmann

Francois Tillequin

Jean-Claude Florent

Michel Azoulay

Claude Monneret

Jean-Claude Jacquesy

Jean-Pierre Gesson

Michel Koch

Original Assignee

Hoechst Ag

Hoechst Houde S A Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-22

Filing date

1994-09-09

Publication date

2000-08-15

1994-09-09 Application filed by Hoechst Ag, Hoechst Houde S A Lab filed Critical Hoechst Ag

2000-08-15 Application granted granted Critical

2000-08-15 Publication of ATE194920T1 publication Critical patent/ATE194920T1/de

Links

229940002612 prodrug Drugs 0.000 title abstract 3
239000000651 prodrug Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Crystallography & Structural Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

AT94114195T 1993-09-22 1994-09-09 Pro-prodrugs, ihre herstellung und anwendung ATE194920T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP93115234		1993-09-22

Publications (1)

Publication Number	Publication Date
ATE194920T1 true ATE194920T1 (de)	2000-08-15

Family

ID=8213288

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94114195T ATE194920T1 (de)	1993-09-22	1994-09-09	Pro-prodrugs, ihre herstellung und anwendung

Country Status (14)

Country	Link
US (1)	US5877158A (de)
EP (1)	EP0648503B1 (de)
JP (1)	JPH07149666A (de)
KR (1)	KR950007875A (de)
AT (1)	ATE194920T1 (de)
AU (1)	AU681180B2 (de)
CA (1)	CA2132608A1 (de)
DE (1)	DE69425356T2 (de)
DK (1)	DK0648503T3 (de)
ES (1)	ES2148259T3 (de)
GR (1)	GR3034412T3 (de)
NZ (1)	NZ264487A (de)
PT (1)	PT648503E (de)
ZA (1)	ZA947332B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5525606A (en)	1994-08-01	1996-06-11	The United States Of America As Represented By The Department Of Health And Human Services	Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
GB9600471D0 (en) *	1996-01-10	1996-03-13	Univ London Pharmacy	Drug delivery system
US6180095B1 (en) *	1997-12-17	2001-01-30	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2312975C (en) *	1997-12-17	2012-08-21	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2497195C (en)	2001-12-14	2014-07-08	The University Of Wyoming	Methods and compositions for controlled release of drugs
US20050203061A1 (en) *	2002-06-20	2005-09-15	Shinya Yamashita	Prodrug, medicinal utilization thereof and process for producing the same
WO2004043493A1 (en) *	2002-11-14	2004-05-27	Syntarga B.V.	Prodrugs built as multiple self-elimination-release spacers
JP2006510626A (ja) *	2002-12-05	2006-03-30	シエーリングアクチエンゲゼルシャフト	増殖疾患の処理における部位特異的供給のためのエポチロン類似体
DE10256982A1 (de)	2002-12-05	2004-06-24	Schering Ag	Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
ZA200507752B (en)	2003-03-28	2007-01-31	Threshold Pharmaceuticals Inc	Compositions and methods for treating cancer
EP1718667B1 (de) *	2004-02-23	2013-01-09	Genentech, Inc.	Heterocyclische, selbst-immolative linker und konjugate
CN102746336B (zh)	2005-06-29	2015-08-19	施瑞修德制药公司	氨基磷酸酯烷化剂前体药物
WO2007149827A2 (en) *	2006-06-20	2007-12-27	Janssen Pharmaceutica, N.V.	Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US20080031866A1 (en) *	2006-06-20	2008-02-07	Eichenbaum Gary M	Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2114157B1 (de)	2006-12-26	2021-05-26	ImmunoGenesis, Inc.	Phosphoramidatalkylator-prodrug für die krebstherapie
US20090118031A1 (en) *	2007-11-01	2009-05-07	Qualizza Gregory K	Shaft Structure with Configurable Bending Profile
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN108883069B (zh) *	2016-01-04	2021-07-20	中央研究院	基于酯化/皂化的用于微脂体负载的方法
US11730826B2 (en)	2016-05-02	2023-08-22	Massachusetts Institute Of Technology	Amphiphilic nanoparticles for delivery of CRISPR based therapy
WO2017197045A1 (en)	2016-05-11	2017-11-16	Movassaghi Mohammad	Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en)	2017-05-11	2018-11-15	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
KR102258299B1 (ko) *	2019-03-21	2021-05-28	고려대학교 산학협력단	대장암 선택적 항암 치료진단제
WO2020247054A1 (en)	2019-06-05	2020-12-10	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN110590875B (zh) *	2019-08-30	2022-08-16	中国药科大学	一种多胺前体脂质及其应用
EP3909612A1 (de)	2020-05-12	2021-11-17	Life Science Inkubator Betriebs GmbH & Co. KG	Zusammensetzung von nanopartikeln
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2024180233A1 (en)	2023-03-02	2024-09-06	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	A therapeutic hpv vaccine based on validated target epitopes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3803124A (en) *	1968-04-12	1974-04-09	Farmaceutici It Soc	Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
NL145536B (nl) *	1968-04-12	1975-04-15	Farmaceutici Italia	Werkwijze voor de bereiding van een nieuw antibioticum of zijn aglycon.
GB1541436A (en) *	1976-02-02	1979-02-28	Searle & Co	Immunological materials
US4337760A (en) *	1978-10-13	1982-07-06	Adolf Schwimmer	Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
FR2439788A1 (fr) *	1978-10-27	1980-05-23	Rhone Poulenc Ind	Nouveaux derives de la daunorubicine, leur preparation et les medicaments qui les contiennent
PL124284B1 (en) *	1979-10-17	1983-01-31	Politechnika Gdanska	Process for preparing n-glycosyl derivatives of antibiotics from anthracyclines group
WO1981001145A1 (en) *	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
IN165717B (de) *	1986-08-07	1989-12-23	Battelle Memorial Institute
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1989006654A1 (en) *	1988-01-19	1989-07-27	Board Of Regents, The University Of Texas System	Glycosides, liposomal compositions thereof, and methods for their use
US5417970A (en) *	1988-10-21	1995-05-23	Sanofi	Drugs containing a glycosylated interleukin-2
DE4002888A1 (de) *	1990-02-01	1991-08-08	Behringwerke Ag	Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
FR2676058B1 (fr) *	1991-04-30	1994-02-25	Hoechst Lab	Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0601417A3 (de) *	1992-12-11	1998-07-01	Hoechst Aktiengesellschaft	Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5618528A (en) *	1994-02-28	1997-04-08	Sterling Winthrop Inc.	Biologically compatible linear block copolymers of polyalkylene oxide and peptide units

1994
- 1994-09-09 DK DK94114195T patent/DK0648503T3/da active
- 1994-09-09 EP EP94114195A patent/EP0648503B1/de not_active Expired - Lifetime
- 1994-09-09 AT AT94114195T patent/ATE194920T1/de not_active IP Right Cessation
- 1994-09-09 ES ES94114195T patent/ES2148259T3/es not_active Expired - Lifetime
- 1994-09-09 PT PT94114195T patent/PT648503E/pt unknown
- 1994-09-09 DE DE69425356T patent/DE69425356T2/de not_active Expired - Fee Related
- 1994-09-20 AU AU74109/94A patent/AU681180B2/en not_active Ceased
- 1994-09-20 NZ NZ264487A patent/NZ264487A/xx unknown
- 1994-09-20 US US08/309,035 patent/US5877158A/en not_active Expired - Fee Related
- 1994-09-21 JP JP6226323A patent/JPH07149666A/ja active Pending
- 1994-09-21 CA CA002132608A patent/CA2132608A1/en not_active Abandoned
- 1994-09-21 ZA ZA947332A patent/ZA947332B/xx unknown
- 1994-09-22 KR KR1019940023833A patent/KR950007875A/ko not_active Ceased
2000
- 2000-09-15 GR GR20000402100T patent/GR3034412T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2132608A1 (en)	1995-03-23
DE69425356D1 (de)	2000-08-31
AU681180B2 (en)	1997-08-21
KR950007875A (ko)	1995-04-15
GR3034412T3 (en)	2000-12-29
AU7410994A (en)	1995-04-06
ZA947332B (en)	1995-05-10
DK0648503T3 (da)	2000-10-02
EP0648503B1 (de)	2000-07-26
JPH07149666A (ja)	1995-06-13
DE69425356T2 (de)	2002-04-18
NZ264487A (en)	1998-12-23
US5877158A (en)	1999-03-02
PT648503E (pt)	2000-11-30
EP0648503A1 (de)	1995-04-19
ES2148259T3 (es)	2000-10-16

Legal Events

Date	Code	Title	Description
2001-02-15	UEP	Publication of translation of european patent specification
2003-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE194920T1 (de)	2000-08-15	Pro-prodrugs, ihre herstellung und anwendung
ATE494009T1 (de)	2011-01-15	Prodrugs, ihre herstellung und verwendung als arzneimittel
DE3673047D1 (de)	1990-09-06	(imidazolyl-4)-piperidine, ihre herstellung und anwendung als heilmittel.
EE200000318A (et)	2001-08-15	Uudsed ühendid
ATE103914T1 (de)	1994-04-15	Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
ATE184602T1 (de)	1999-10-15	Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
FI942074A0 (fi)	1994-05-05	nor-sappijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
ATE151764T1 (de)	1997-05-15	Neue benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltenden zubereitungen
DK314487D0 (da)	1987-06-19	Benzoxepinderivat
ES2127181T3 (es)	1999-04-16	11-beta-aril-gona-4,9-dien-3-onas.
DE3677842D1 (de)	1991-04-11	Verfahren zur herstellung von piperidyliden-dihydrodibenzo(a,d)zykloheptenen und deren azoderivate, so hergestellte verbindungen und ihre anwendung zur vorbereitung von heilmitteln.
CZ282732B6 (cs)	1997-09-17	Substituované 1,2,3,4-tetrahydrocyklopent/b/indoly, 1,2,3,3a,4,8a-hexahydrocyklopent/b/indoly a příbuzné sloučeniny, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv
GR1001597B (el)	1994-06-30	Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DE3874206D1 (de)	1992-10-08	2-(3-4-dihydroxyphenyl)-aethylamine, ihre herstellung und ihre verwendung als arzneimittel.
ATE94764T1 (de)	1993-10-15	Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
MX9604762A (es)	1997-04-30	Nuevas sulfonamidas y procedimiento para su preparacion.
LV10870A (lv)	1995-10-20	Jauni fosfolipidu atvasinajumi
ATE243683T1 (de)	2003-07-15	Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln
DE69804766D1 (de)	2002-05-16	Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
BR9101973A (pt)	1991-12-24	Compostos quimicos,processo para a sua preparacao e composicoes farmaceutica e terapeutica
ATE205210T1 (de)	2001-09-15	2-azabicyclo(2.2.1)heptan-derivate, ihre herstellung und ihre anwendung
ATE89552T1 (de)	1993-06-15	Guanidin-derivate, ihre herstellung und insektizide.
ATE67765T1 (de)	1991-10-15	Imidazopyridinderivate, ihre herstellung und therapeutische verwendung.